{"id":"W3042347895","doi":"10.1002/cncr.33033","title":"Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial","year":2020,"lang":"en","type":"article","venue":"Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":337,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Everolimus; Open label; Randomized controlled trial; Renal cell carcinoma; Internal medicine; Oncology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001878095,0.0003589704,0.001108384,0.00006627686,0.00006456853,0.00002496362,0.0003513111,0.0000915008,0.0001077534],"category_scores_gemma":[0.0000824598,0.0002002691,0.0001208469,0.0004795381,0.0001941967,0.0001610983,0.0001403405,0.0002791507,0.000007436784],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004040289,"about_ca_system_score_gemma":0.000627242,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000345294,"about_ca_topic_score_gemma":0.0002318425,"domain_scores_codex":[0.9976086,0.0001936144,0.0006414694,0.0005883377,0.0005836302,0.0003843502],"domain_scores_gemma":[0.9983243,0.0000959982,0.0004931639,0.0006024143,0.000255013,0.00022909],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9870676,0.0008260184,0.008377138,0.0000882001,0.0002570493,0.00008956008,0.0006966615,0.00007324234,0.0006261039,0.000001511302,0.000514941,0.001382023],"study_design_scores_gemma":[0.946797,0.008959764,0.01806979,0.0002151184,0.0008156613,0.000001365279,0.00003475232,0.00007457851,0.02469602,8.562413e-7,0.0001109059,0.0002242192],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915934,0.0005228182,0.000008849045,0.0004113722,0.0003954592,0.005395916,0.0001876068,0.00002297224,0.001461668],"genre_scores_gemma":[0.998325,0.00002953981,0.0001457267,0.0001972001,0.00009796747,0.0003671753,0.0002312292,0.00005421231,0.0005519725],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04027057,"threshold_uncertainty_score":0.8166739,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03662694787433408,"score_gpt":0.2968996984932093,"score_spread":0.2602727506188752,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}